Products
Dupilumab Biosimilar Monoclonal Antibody (IL-4Rα) for Research
Pre-Made Dupilumab biosimilar, Whole mAb, Anti-IL4R Antibody: Anti-CD124 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody used for allergic diseases such as eczema (atopic dermatitis), asthma and nasal polyps which result in chronic sinusitis.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-158-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Dupilumab biosimilar, Whole mAb, Anti-IL4R Antibody: Anti-CD124 therapeutic antibody |
| INN Name | Dupilumab |
| Target | IL4R |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 6wgb:AB:CD/6wgj:AB:CD:EF/6wgk:AB:CD:EF:GH/6wgl:AB/6wg8:AB |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2012 |
| Year Recommended | 2013 |
| Companies | Aimmune Therapeutics;Regeneron Pharmaceuticals;Sanofi |
| Conditions Approved | Asthma;Atopic dermatitis;Nasal polyps |
| Conditions Active | Chronic obstructive pulmonary disease;Eosinophilic oesophagitis;Grass pollen hypersensitivity;Peanut hypersensitivity;Urticaria |
| Conditions Discontinued | Allergic asthma |
| Development Tech | VelocImmune Mouse |
About target - IL4R
1. Protein Interleukin-4 receptor subunit alpha
2. Gene IL4R
3. Organism Homo sapiens (Human)
Function
Receptor for both interleukin 4 and interleukin 13. Couples to the JAK1/2/3-STAT6 pathway. The IL4 response is involved in promoting Th2 differentiation. The IL4/IL13 responses are involved in regulating IgE production and, chemokine and mucus production at sites of allergic inflammation. In certain cell types, can signal through activation of insulin receptor substrates, IRS1/IRS2.
Soluble IL4R (sIL4R) inhibits IL4-mediated cell proliferation and IL5 up-regulation by T-cells.
